Looking forward, the human respiratory syncytial virus treatment market is set to continue its robust growth trends. The market size is forecasted to reach $2.58 billion by 2029, growing at a CAGR ...

In babies, RSV is a common cause of a type of chest infection called bronchiolitis. Last week, the UK Health Security Agency ...

For infants born from October to February, maternal vaccination was cost-effective, but compared with vaccination, nirsevimab ...

HMPV is in the Pneumoviridae family along with respiratory syncytial virus (RSV), and was discovered in 2001, according to the B.C. Centre for Disease Control.

A mix of respiratory viruses continues to circulate in B.C., such as respiratory syncytial virus and the virus that causes COVID-19. It’s called the human metapneumovirus (HMPV) and while for ...

Older adults are at increased risk of hospital admission, intensive care unit admission, and death due to respiratory syncytial virus (RSV) 1 Most people experience mild RSV reinfections throughout ...

ORAL PRESENTATION October 1, 2022, 09:45 – 10:00 BST “EDP-323, a Novel L-Protein Inhibitor for the Treatment of Respiratory Syncytial Virus,” Michael Rhodin, Ph.D., United States ...

54. A study to evaluate the safety and efficacy of mRNA-1345 vaccine targeting respiratory syncytial virus (RSV) in adults ≥60 years of age. ClinicalTrials.gov. Updated May 31, 2024.

The human metapneumovirus (hMPV) is a common respiratory virus that typically causes mild cold-like symptoms. Studies show it has circulated in human populations since the 1970s, though it was ...

Chicago, June 09, 2025 (GLOBE NEWSWIRE) -- The global respiratory syncytial virus treatment market valued at USD 2,387.2 million in 2024 and is projected to reach USD 8,332.5 million by 2033 ...